Article

PRODUCT SPECTRUM

FDA APPROVES B+L’S LOTEMAX SM

Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. Compared to Lotemax Gel (loteprednol etabonate ophthalmic gel) 0.5%, Lotemax SM delivers a submicron particle size for faster drug dissolution in tears, and it provides two times greater penetration to the aqueous humor, according to the company. Lotemax SM also contains moisturizing ingredients (glycerin and propylene glycol), a pH close to that of human tears, and the lowest preservative percentage (0.003% benzalkonium chloride [BAK]) in a loteprednol etabonate formulation, according to the company. B+L expects to make Lotemax SM available by April 2019. Call (800) 828-9030 or visit www.bausch.com . ■

Lotemax SM delivers a submicron particle size designed for faster drug dissolution in tears.

ALCON DEBUTS ILUX

Alcon recently launched the iLux MGD Treatment System to the eyecare professional community. The device, which received clearance from the U.S. Food and Drug Administration in December 2017, is a handheld, portable device for in-office use that is indicated for the application of localized heat and pressure therapy in adult patients who have chronic disease of the eyelids, including meibomian gland dysfunction. It features a Smart Tip Patient Interface that enables practitioners to directly target a patient’s blocked meibomian glands through the application of light-based heat and compression under direct visualization, according to the company. Alcon says that iLux allows practitioners to tailor treatment to the needs of each of their patients who have dry eye disease in a matter of minutes. Call (800) 451-3937 or visit www.alcon.com .

iLux is an in-office device designed to allow practitioners to tailor meibomian gland treatments for their dry eye patients.

BRUDER INTRODUCES HYGIENIC EYELID SOLUTION

Bruder Healthcare now offers Bruder Hygienic Eyelid Solution, a 0.02% pure hypochlorous acid solution that the company says is safe for daily, long-term use. This solution contains no alcohol, oil, sulfates, parabens, or added fragrance, making it an ideal foundation for good eyelid health and a beneficial addition to a daily eye-care regimen for patients who have mild or moderate conditions, according to the company. Bruder says that the spray application is soothing to sensitive skin and provides fast relief from dryness and from itchy, inflamed skin. It is available in two sizes—1 fl oz (30mL) and 2 fl oz (60mL). The solution is sprayed on the eyelids with no need to rinse or wipe, according to the company. Call (888) 827-8337 or visit www.bruder.com .

Bruder’s new hypochlorous acid spray.

EAGLET EYE UPGRADES EYE SURFACE PROFILER

Eaglet Eye b.v. announced a major upgrade to its Eye Surface Profiler (ESP) software. In addition to bringing the total number of designs embedded to more than 35, the software can now calculate four quadrant peripheries, bitoric sclerals, and toric haptics. According to the company, the most significant upgrade is SmartMerge, which allows practitioners to combine up to five full images. This allows full functionality (optimal coverage) should one image not have sufficient data. The ESP upgrade is available to users worldwide. Visit www.eaglet-eye.com or email info@eaglet-eye.com.